Heparin Sodium
The sodium salt form of heparin, a widely used injectable anticoagulant that prevents clot formation by enhancing the activity of antithrombin against multiple clotting factors. This is the standard pharmaceutical formulation of heparin available for intravenous and subcutaneous administration. Bleeding risk, platelet counts, and clotting times must be monitored during therapy.
Peso Molecular
1157,9000 g/mol
TPSA
652,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose …
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
InChI
InChI=1S/C26H42N2O37S5.Na/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+1
Molecular Formula
C26H42N2NaO37S5+
HBD / HBA
15 / 38
Ligações Rotacionáveis
21
Átomos Pesados
71
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The sodium salt form of heparin, a widely used injectable anticoagulant that prevents clot formation by enhancing the activity of antithrombin against multiple clotting factors. This is the standard pharmaceutical formulation of heparin available for intravenous and subcutaneous administration. Bleeding risk, platelet counts, and clotting times must be monitored during therapy.
Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.
Yes, Heparin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201657. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 92044406. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="heparin-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/heparin-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/heparin-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/heparin-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="heparin-sodium"></drugfyi-drug>